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 Case Report 
 A 58-year-old human immunodeficiency virus (HIV)-
negative man was diagnosed with B cell chronic lymphat-
ic leukemia (CLL) of Binet stage C in 1995. In 2002, dis-
ease progression necessitated the administration of 6 cy-
cles of fludarabine (FAMP;  table 1 ). The patient’s health 
status deteriorated in October 2003, and chemotherapy 
was altered to the CHOP 21 regimen (doxorubicin, cyclo-
phosphamide, vincristine and prednisone;  table 1 ). Treat-
ment was discontinued after 3 cycles due to unrespon-
siveness. After 2 relapses of B cell CLL, complete remis-
sion was achieved by treatment with alemtuzumab 
( table 1 ). The patient was subsequently referred for HLA-
DR mismatched allogeneic stem cell transplantation 
(SCT) in late January 2004. Reduced-intensity condition-
ing consisted of FAMP, busulfan and alemtuzumab ( ta-
ble 1 ). Graft-versus-host disease (GvHD) prophylaxis was 
initially carried out with cyclosporin A, but was switched 
to tacrolimus due to side effects ( table 1 ). Twelve days af-
ter SCT the patient developed acute skin GvHD, which 
responded to prednisolone therapy. On day 40 after SCT, 
cytomegalovirus reactivation occurred (pp65 antigen-
emia: 2 positive cells/100,000 leukocytes) and was suc-
cessfully treated by valganciclovir medication for 5 weeks. 
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 Abstract 
 We report on a stem cell-transplanted patient with B cell 
chronic lymphatic leukemia who presented with a subacute 
onset of focal neurological deficits, gait abnormalities, emo-
tional lability and dementia. Progressive multifocal leukoen-
cephalopathy was diagnosed by magnetic resonance imag-
ing (MRI) of the brain and detection of JC virus genome in 
the cerebrospinal fluid. Cidofovir and the 5HT2A receptor 
antagonist chlorpromazine were subsequently adminis-
tered. A follow-up MRI of the brain 2 weeks after initiation of 
the antiviral therapy displayed progress of the demyelin-
ation, and the patient died 3 months after onset of the neu-
rological symptoms. This report highlights the need for the 
development of novel and potent strategies for treatment of 
progressive multifocal leukoencephalopathy. 
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Four months after transplant, a relapse of skin GvHD re-
quired repeated steroid treatment with prednisolone. 
Two weeks later the patient complained of drowsiness, 
vertigo, slight tremor and erratic mood swings which 
worsened during the next days. Clinical examination re-
vealed bilateral homonymous hemianopsia of his right 
field of vision. A brain magnetic resonance imaging 
(MRI) showed an area of demyelination in the left oc-
cipital lobe of the brain ( fig. 1 b, left panel). No typical 
signs of infarction or tumor were detected.
 Biochemical analysis of the cerebrospinal fluid (CSF) 
revealed signs of nonspecific inflammation, with mild 
lymphocytic pleocytosis (18 megaparticles/l, normal  ! 5 
megaparticles/l) and a slight increase in glucose (8.07 
mmol/l, normal 2.8–4.4 mmol/l), total protein (639 mg/l, 
normal 130–400 mg/l) and lactate (3.18 mmol/l, normal 
1.2–2.1 mmol/l). In addition, neither bacterial nor fungal 
DNA was detectable in CSF by PCR, nor were neurotrop-
ic viruses (herpes simplex 1/2, varicella-zoster virus, cy-
tomegalovirus, Epstein-Barr virus, human herpes virus 
Table 1. Posology and time of administration of the drugs in the course of the patient’s stem cell transplanta-
tion
Drug Posology1 Year/time period
relative to SCT2
Fludarabine 25 mg/m2; 6 cycles 2002
CHOP (doxorubicin
cyclophosphamide, vincristine and
prednisone)
doxorubicin 25 mg/m2, cyclophosphamide
300 mg/m2, vincristine 1 mg/m2 and
prednisone 40 mg/m2; 3 cycles in total
2003
Alemtuzumab (Campath-1H) 30 mg; 20 applications in total 2004
Fludarabine 30 mg/m2 2004/d–9 to d–5
Busulfan 4!1 mg/kg 2004/d–4 to d–3
Alemtuzumab (Campath-1H) 5 mg 2004/d–9
10 mg 2004/d–8
20 mg 2004/d–7 to d–5
Prednisolone 50 mg 2004/d–9 to d–5
80 mg tapered to 30 mg over 2 months 2004/1+20
80 mg 2004/d+136 to d+183
80 mg tapered to 20 mg 2004/d+184
Cyclosporin A 2!150 mg 2004/d–1 to d+1
2!175 mg 2004/d+2 to d+3
2!200 mg 2004/d+4 to d+5
1!200/225 mg 2004/d+6 to d+11
2!200 mg 2004/d+12
2!150 mg 2004/d+13 to d+19
Tacrolimus 2!1 mg 2004/d+19
Cidofovir 5 mg/kg, once per week 2004/d+173 and d+180
Probenicid 2 g, 3 h before CDV application; 2004/d+173 and d+180
1 g, 2 and 8 h thereafter
Chlorpromazine 3!200 mg
3!400 mg
3!200 mg
3!400 mg
3!200 mg
2004/d+173
2004/d+174 to d+186
2004/d+187 to d+198
2004/d+199 to d+201
2004/d+202
1 The posology corresponds to the dose per day, except for cidofovir which is administered weekly.
2 The days before (d–) and after (d+) stem cell transplantation (SCT) are shown.
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6/8, adeno- and enterovirus) except for JC virus (JCV). JC 
viral load was determined in both CSF and peripheral 
blood by real-time PCR using 2 different protocols  [1, 2] . 
Mean values for CSF and peripheral blood were 7.3  ! 10 5 
and 7.2  ! 10 3 copies/ml, respectively, indicating system-
ic infection ( fig. 1 a). Antiviral treatment including cido-
fovir (CDV) with concomitant probenicid, chlorproma-
zine and immunoglobulins was initiated ( table 1 ). A fol-
low-up brain MRI 2 weeks after therapy initiation 
evidenced multiple areas of demyelination ( fig. 1 b, right 
panel). The JC viral load in CSF and peripheral blood 
showed no significant decrease despite antiviral treat-
ment ( fig. 1 a). The disease progressed to blindness, deaf-
ness and disorientation as well as fecal and urinary in-
continence. The patient died from progressive multifocal 
leukoencephalopathy (PML) 8 months following trans-
plant and 3 months after onset of the first neurological 
symptoms.
 Discussion 
 We report on an HIV-negative patient diagnosed with 
PML following allogeneic SCT and immunosuppressive 
treatment ( table 1 ), in whom JC viral load was monitored 
in plasma and CSF under anti-JCV-specific therapy. In 
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
G
e
n
o
m
e
e
q
u
iv
a
le
n
ts
/m
l
9
5
1
0
3
1
0
9
1
2
3
1
2
9
1
3
0
1
4
3
1
5
1
1
6
4
1
7
3
1
7
7
1
7
9
1
8
4
Days after SCT
Symptoms
Cidofovir
JCV load in plasma
a
0
250,000
500,000
750,000
1,000,000
1,250,000
1,500,000
1,750,000
2,000,000
G
e
n
o
m
e
e
q
u
iv
a
le
n
ts
/m
l
1
6
6
Days after SCT
JCV load in CSF
1
7
8
 Fig. 1. Diagnosis and evolution of progres-
sive multifocal encephalopathy under 
therapy.  a Dynamics of the JC virus (JCV) 
load in the plasma and cerebrospinal fluid 
(CSF) of the patient under cidofovir thera-
py. The viral load in the plasma (left panel) 
and cerebrospinal fluid (right panel) of the 
patient was determined by real-time PCR. 
The viral load represents the mean and 
standard error of 3 independent measures. 
Onset of the symptoms and cidofovir ad-
ministration as indicated.  b Magnetic res-
onance imaging (MRI) of the brain. Axial 
brain MRI in FLAIR sequences. Left: de-
myelinating lesion of high signal intensity 
in the left occipital lobe, paraventricular to 
the lateral ventricle. Right: demyelinating 
lesion of high signal intensity, progressive 
in size, encompassing both the left occipi-
tal and temporal lobe. New subcortical le-
sion of high signal intensity is located in 
the right occipital lobe. 
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the course of 2-fold CDV application, a 40–60% decrease 
in JC viral load in plasma samples was observed shortly 
after drug administration ( fig. 1 a, left panel), whereas JC 
viral load in CSF samples in fact doubled (mean values: 
7.3  ! 10 5 vs. 1.5  ! 10 6 genome equivalents/ml;  fig. 1 a, 
right panel). According to our observations, combined 
anti-JCV-specific therapy with CDV and chlorpromazine 
was ineffective in significantly lowering JCV plasma and 
CSF loads and thus providing a clinical benefit for our 
patient. In this context, possible mechanisms for the non-
response of the anti-JCV-specific therapy are discussed.
 PML is a subacute demyelinating disease of the central 
nervous system (CNS) with a grim prognosis  [3] caused 
by the neurotropic virus JC, a double-stranded DNA vi-
rus of the Polyomaviridae family. In immunocompro-
mised patients, reactivation of JCV leads to various symp-
toms ranging from acute febrile illness to PML  [4] . So far, 
various treatment regimens have been discussed. They 
mainly consist of 2 therapeutic approaches: inhibition of 
viral replication in the host cell, and a most novel ap-
proach based on inhibition of virus entry into host cells.
 The first therapeutic approach is based upon inhibi-
tion of viral replication in host cells by using drugs with 
antiviral activity against Polyomaviridae, such as CDV 
and cytosine arabinoside  [5, 6] . CDV is a deoxycytidine 
 monophosphate analogue, with broad in vitro and in 
vivo activity against DNA viruses of various families 
(Adenoviridae, Herpesviridae and Polyomaviridae)  [5, 6] . 
In vitro studies showed that CDV inhibits replication of 
mouse polyomavirus and Simian virus 40  [5] , and dis-
plays efficacy against JCV multiplication in persistently 
infected human fetal brain cell lines  [7] . A scarce number 
of anecdotal reports describe possible benefits of CDV 
treatment in PML, specifically in HIV-negative CLL pa-
tients suffering from PML  [8, 9] .
 However, it remains unclear whether the improve-
ments of symptoms in those patients is the net result of 
the antiviral effects of CDV, or of the immune reconstitu-
tion that follows successful cytostatic CLL therapy. Of 
note, intravenous administration of CDV does not yield 
detectable CSF concentrations ( ! 0.1 mg/ml, assay detec-
tion threshold, data from Gilead Sciences Inc.), indicat-
ing that CDV does not diffuse through the blood-brain 
barrier. Qalbumin (concentration of albumin in CSF/con-
centration of albumin in plasma) was normal in our pa-
tient, excluding a substantial CNS barrier dysfunction. 
However, small leaks in the blood-brain barrier allowing 
CDV to enter the CNS cannot be completely ruled out in 
PML despite normal Qalbumin. Whether sufficient CSF 
drug levels for inhibition of viral replication are reached 
is an open question. Due to limited specimens, intrathe-
cal levels of CDV and its metabolites could not be mea-
sured in our case. In view of the rising JC viral load in 
CSF and disease progression despite CDV therapy, intra-
thecal drug concentrations may not have reached suffi-
ciently high levels to display antiviral effects, thus con-
tributing to treatment failure.
 The second and novel therapeutic approach relies on 
the use of neurotropic drugs to inhibit JCV entry into the 
host cell and subsequent viral spread. The rationale for 
this approach is based on the observation that the seroto-
nergic receptor 5HT2A acts as the cellular receptor for 
JCV on human glial cells  [10] . 5HT2A receptor antago-
nists like chlorpromazine and clozapine effectively in-
hibit JCV infection of glial cells and the spread of JCV 
through tissues, by blocking the clathrin-dependent en-
docytosis that enables cellular JCV uptake  [11] . However, 
the clinical efficacy of this drug class in treating PML has 
not been evaluated yet. In our case, progress of the demy-
elinating lesions was evidenced by brain MRI 2 weeks 
after initiation of the treatment, indicating that JCV 
spread within the white matter of the brain could not be 
impeded by chlorpromazine ( fig. 1 b, right panel). The 
continuous development of new brain foci as shown in 
our patient by MRI ( fig. 1 b, right panel) is concordant 
with a lytic infection including viral spread from cell to 
cell and high quantities of tissue-associated virus. Chlor-
promazine interference with 5HT2A receptor-mediated 
clathrin-dependent endocytosis targets an early step in 
the viral life cycle. Drug application early in the course of 
the disease may thus be crucial to achieve a clinical ben-
efit, as glial cells already harboring/having internalized 
the virus are left unaffected by chlorpromazine  [11] . Fur-
thermore, overall viral mass in tissue may constitute a 
critical factor as both virus particles and chlorpromazine 
compete for the same cell receptor. Newer atypical anti-
psychotics with less adverse effects, like risperidone or 
olanzapine, have proven to be significantly more potent 
5HT2A receptor antagonists in vitro than chlorproma-
zine or clozapine  [12] , which may render them more ide-
al candidates for the treatment and/or prophylaxis of 
PML in immunodeficient patients.
 Cell-mediated immunity is essential in the control of 
many viral infections in humans and has also been sug-
gested to play a crucial role in the containment of JCV 
 [13–15] . Therefore, it is likely that immunosuppressant 
drugs not only trigger JCV reactivation in immunocom-
promised patients but sustainably influence the course 
and prognosis of PML. Infectious complications associ-
ated with calcineurin inhibitors, for example cyclosporin 
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A and tacrolimus, include other viral infections  [16] of 
which BK virus reactivation represents a significant cause 
of allograft failure in renal transplant recipients  [17] . Fur-
thermore, cyclosporin A has been associated with the oc-
currence of PML in patients suffering from rheumatic 
diseases  [18, 19] . The development of PML has also been 
observed in patients receiving corticosteroids for rheu-
matic disease  [20–24] . A correlation between JC viruria 
and corticosteroid treatment has been demonstrated in 
one study  [25] . Purine nucleoside analogues, primarily 
FAMP, inducing a rapid T lymphocyte decline render re-
cipients particularly prone to various opportunistic in-
fections  [26] and have also been linked to the develop-
ment of PML  [9, 27–29] . Alemtuzumab, used as consoli-
dation therapy in CLL patients, in preparation for SCT, 
or to avert acute and chronic GvHD, provokes increased 
vulnerability to infections due to profound and sustained 
lymphocyte depletion  [30] as demonstrated by several 
clinical trials  [31–33] . Polyomavirus – that is BK virus – 
infections have been described in renal transplant recipi-
ents  [34] , whereas JCV reactivation after administration 
of alemtuzumab has not been reported so far in the lit-
erature. Considering the immune-modulating therapy 
regimens given to our patient ( table 1 ), it is conceivable 
that the underlying immunosuppression may account for 
the nonresponse of the anti-JCV-specific therapy by 
countervailing the antiviral effects of CDV and chlor-
promazine.
 In conclusion, the use of 5HT2A receptor antagonists 
like chlorpromazine in addition to CDV may represent, 
if administered early in the course of the disease or given 
prophylactically, a possible strategy for treatment/pre-
vention of PML. Further studies providing both experi-
mental and clinical data are needed to evaluate the ben-
efit of this strategy for treatment and/or prophylaxis of 
PML.
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